'Virtual biopsy' device developed to detect skin tumors
Scientists at Rutgers University have developed a new "virtual biopsy"
device capable of quickly determining a skin lesion's depth and potential malignancy without the use of a scalpel. Using sound vibrations and pulses of near-infrared light, the researchers tested the device to identify a lesion's borders and areas of greatest density and stiffness, which would potential allow practitioners to remove tumors with minimally invasive surgery. In a statement, Lead researcher Frederick Silver, a professor of pathology and laboratory at Rutgers Robert Wood Johnson Medical School explained: This procedure can be completed in 15 minutes with no discomfort to the patient, who feels no sensation from the light or the nearly inaudible sound. It's a significant improvement over surgical biopsies, which are invasive, expensive and time consuming." The VOCT device awaits further supporting research for FDA approval.
Topical demonstrates efficacy for molluscum contagiosum treatment
A new drug-device combination, VP-102, Verrica
, containing a topical formulation of cantharidin has demonstrated promise in the treatment of molluscum contagiosum in the results of a phase three randomized double blind controlled trial. Molluscum contagiosum is a highly contagious pediatric infection caused by DNA poxvirus, molluscum contagiosum virus. In a statement, Lawrence Eichenfield, MD-- SBS faculty member and lead investigator for the VP-102 phase 3 molluscum program--shared: “The high lesion clearance rate demonstrated at day 84 for VP-102 compared to placebo in the phase 3 trials is clinically significant and could potentially position VP-102 to become the standard of care for treating molluscum.” Currently, there are no treatments for molluscum contagiousum approved by the U.S. Food and Drug Administration.
Steroid-free atopic dermatitis topical completes phase 4 trial
In the recent results of a phase 4 trial
, Crisaborole ointment, 2% (Eucrisa, Pfizer) appear to be safe and effective in young children aged three months to less than two year who have mild-to-moderate atopic dermatitis. According to a press release, the CrisADe Care 1 trial analyzed the number of patients with treatment-emergence adverse events and severe adverse events alongside the number of patient with clinically significant changes from baselines in height, weight, vital signs, and clinical laboratory parameters. The ointment--currently available in the U.S., Canada, Australia, and Israel--is a steroid-free topic phosphodiesterase inhibitor.
Your Last Chance At Our Lowest Early Bird Prices!
Register today to save on the 18th Annual South Beach Symposium
before prices increase tomorrow, August, 1